Correction to: Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-021-00713-1, published online 9 August 2021
After online publication of the article1, the authors noticed one inadvertent mistake occurred during the production process in Fig. 7 that needs to be corrected. The correct data are provided as follows. The key findings of the article are not affected by these corrections. The original article has been corrected.
e Flow cytometry assessing the proportion of CD4/8+ cells with fluorescent antibodies against the cell markers indicated.
References
Zhu, Q. et al. AHR mediates the Aflatoxin B1 toxicity associated with hepatocellular carcinoma. Signal Transduct. Target Ther. 6, 299 (2021).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhu, Q., Ma, Y., Liang, J. et al. Correction: AHR mediates the Aflatoxin B1 toxicity associated with hepatocellular carcinoma. Sig Transduct Target Ther 6, 432 (2021). https://doi.org/10.1038/s41392-021-00794-y
Published:
DOI: https://doi.org/10.1038/s41392-021-00794-y
This article is cited by
-
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Signal Transduction and Targeted Therapy (2025)
